Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 3/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7745287 | 0.95 | PTGER4 (0.51) | PTGER4CHRM2NCF1HDAC3HDAC1 | |
| SCHEMBL742957 | 0.87 | PTGER4 (0.54) | PTGER4NCF1HDAC3HDAC1HDAC2 | |
| Hydrochloric Acid SCHEMBL11314258 | 0.86 | PTGER4 (0.53) | PTGER4CHRM2NCF1HDAC3HDAC1 | |
| SCHEMBL215272 | 0.85 | HDAC3 (0.50) | CHRM2HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL6247309 | 0.83 | HDAC3 (0.53) | CHRM2HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL8720375 | 0.83 | HDAC3 (0.53) | CHRM2HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL18394468 | 0.81 | PTGER4 (0.46) | PTGER4CHRM2NCF1HDAC3HDAC1 | |
| SCHEMBL867417 | 0.81 | PRSS1 (0.47) | HDAC3HDAC1HDAC2NCOR2HDAC6 | |
| SCHEMBL10408715 | 0.81 | HTT (0.62) | PTGER4CHRM2NCF1HDAC1KCNH3 | |
| SCHEMBL1170549 | 0.80 | TLR8 (0.49) | CHRM2HDAC3HDAC1HDAC2NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297114-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2018-06-06 | — | — | EP | disclosed |
| US-20160046601-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2016-02-18 | — | — | US | disclosed |
| US-20160046601-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2016-02-18 | — | — | US | disclosed |
| US-20160046601-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2016-02-18 | — | — | US | disclosed |
| US-9221836-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-29 | — | — | US | disclosed |
| US-9221836-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-29 | — | — | US | disclosed |
| US-9221836-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-29 | — | — | US | disclosed |
| CN-103373985-B | Heterocyclic compounds and their use | TAKEDA PHARMACEUTICAL CO.,LTD. (JP) | 2015-10-28 | — | — | CN | disclosed |
| US-20150191486-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-07-09 | — | — | US | disclosed |
| US-20150191486-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-07-09 | — | — | US | disclosed |
| US-20120264733-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | SCOHIA PHARMA, INC. (JP) | 2012-10-18 | — | — | US | disclosed |
| US-20110178057-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| US-20110178057-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| US-20110178057-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| EP-2297114-A2 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-03-23 | — | — | EP | disclosed |
| US-20100137587-A1 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-06-03 | — | — | US | disclosed |
| US-20100137587-A1 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-06-03 | — | — | US | disclosed |
| US-20100137587-A1 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-06-03 | — | — | US | disclosed |
| WO-2009154300-A2 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009154300-A2 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264733-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | REN, AGT, ACE | PTGER4 459/4885CHRM2 3375/4885NCF1 2540/4885 |
| US-20110178057-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | REN, AGT, ACE | PTGER4 291/4885CHRM2 2659/4885NCF1 2414/4885 |
| US-20150191486-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | REN, AGT, ACE | PTGER4 459/4885CHRM2 3375/4885NCF1 2540/4885 |
| US-20160046601-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | REN, AGT, ACE | PTGER4 459/4885CHRM2 3375/4885NCF1 2540/4885 |
| US-20100137587-A1 | Heterocyclic compound and use thereof | REN, AGT, ACE | PTGER4 459/4885CHRM2 3375/4885NCF1 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.